Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kupert, Elena ^a   Anderson, Marshall ^a   Liu, Yin ^a   Succop, Paul ^a   Levin, Linda ^a   Wang, Jiang ^a   Wikenheiser brokamp, Kathryn ^a   Chen, Pingping ^a   Pinney, Susan M ^a   Macdonald, Trudy ^a   Dong, Zhongyun ^a   Starnes, Sandra ^a   Lu, Shan ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; SECRETORY PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 IIA; TUMOR MARKER; UNCLASSIFIED DRUG; PHOSPHOLIPASE A2 GROUP II;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; LUNG TUMOR; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOLITARY PULMONARY NODULE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 83055187855     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-513     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: A CancerJ Clin 2009, 59(4):225-249.
2. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009, 136(1):260-271. 10.1378/chest.08-0978, 19584208.
3. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354(9173):99-105. 10.1016/S0140-6736(99)06093-6, 10408484.
4. Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl):94S-107S.
5. Starnes SL, Reed MF, Meyer CA, Shipley RT, Jazieh AR, Pina EM, Redmond K, Huffman LC, Pandalai PK, Howington JA. Lung cancer screening with low-dose CT in an area endemic for Histoplasma Capsulatum: minimizing invasive procedures for benign nodules. J Thorac Cardiovasc Surg 2011, 141:688-693. 10.1016/j.jtcvs.2010.08.045, 20933243.
6. Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, Naidich DP, Ost DE. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines. Chest 2007, 132(3 Suppl):108S-130S. 2.
7. Oxnard GR, Zhao B, Sima CS, Ginsberg MS, James LP, Lefkowitz RA, Guo P, Kris MG, Schwartz LH, Riely GJ. Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes. J Clin Oncol 2011,
8. Edey AJ, Hansell DM. Incidentally detected small pulmonary nodules on CT. Clin Radiol 2009, 64(9):872-884. 10.1016/j.crad.2009.03.006, 19664477.
9. Ghosal R, Kloer P, Lewis KE. A review of novel biological tools used in screening for the early detection of lung cancer. Postgrad Med J 2009, 85(1005):358-363. 10.1136/pgmj.2008.076307, 19581246.
10. Amur S, Frueh FW, Lesko LJ, Huang SM. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med 2008, 2(3):305-311. 10.2217/17520363.2.3.305, 20477416.
11. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009, 339:b3527. 10.1136/bmj.b3527, 19773328.
12. Tufman A, Huber RM. Biological markers in lung cancer: A clinician's perspective. Cancer Biomark 2010, 6(3-4):123-135.
13. Cummings BS. Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 2007, 74(7):949-959. 10.1016/j.bcp.2007.04.021, 17531957.
14. Triggiani M, Granata F, Giannattasio G, Marone G. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. The J Allergy Clin Immunol 2005, 116(5):1000-1006.
15. Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O'Leary E, You M, Bonventre JV, Nemenoff RA, Malkinson AM. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinog 2004, 25(8):1517-1524.
16. Antonio V, Brouillet A, Janvier B, Monne C, Bereziat G, Andreani M, Raymondjean M. Transcriptional regulation of the rat type IIA phospholipase A2 gene by cAMP and interleukin-1beta in vascular smooth muscle cells: interplay of the CCAAT/enhancer binding protein (C/EBP), nuclear factor-kappaB and Ets transcription factors. The Biochem J 2002, 368(Pt 2):415-424.
17. Dong Z, Liu Y, Scott KF, Levin L, Gaitonde K, Bracken RB, Burk B, Zhai Q, Wang J, Oleksowicz L, et al. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for Prostate Cancer. Carcinog 2010, 31:1948-1955.
18. Kallajoki M, Alanen KA, Nevalainen M, Nevalainen TJ. Group II phospholipase A2 in human male reproductive organs and genital tumors. The Prostate 1998, 35(4):263-272. 10.1002/(SICI)1097-0045(19980601)35:4<263::AID-PROS5>3.0.CO;2-H, 9609549.
19. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, Zhang S, Eckert GJ, Koch MO, Eble JN, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. The Am J Pathol 2002, 160(2):667-671.
20. Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001, 7(12):3857-3861.
21. Sved P, Scott KF, McLeod D, King NJ, Singh J, Tsatralis T, Nikolov B, Boulas J, Nallan L, Gelb MH, et al. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 2004, 64(19):6934-6940. 10.1158/0008-5472.CAN-03-3018, 15466184.
22. Dong Z, Liu Y, Levin L, Oleksowicz L, Wang J, Lu S. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer. Oncology Reports 2011, 25(6):1511-6.
23. Oleksowicz L, Liu Y, Bracken RB, Gaitonde K, Burke B, Succop P, Levin L, Dong ZY, Lu S. Secretory Phospholipase A2-IIa is a Target Gene of the HER/HER2-Elicited Pathway and Potential Plasma Biomarker for Poor Prognosis of Prostate Cancer. The Prostate 2011,
24. Dong ZY, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endo 2006, 20:2315-2325.
25. Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiol 2005, 16(1):73-81.
26. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003, 24(4):209-218. 10.1159/000074432, 14654716.
27. Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995, 108(1):163-169. 10.1378/chest.108.1.163, 7541742.
28. Glasser SW, Korfhagen TR, Wert SE, Bruno MD, McWilliams KM, Vorbroker DK, Whitsett JA. Genetic element from human surfactant protein SP-C gene confers bronchiolar-alveolar cell specificity in transgenic mice. Am J Physiol 1991, 261(4 Pt 1):L349-356.
29. Wikenheiser KA, Clark JC, Linnoila RI, Stahlman MT, Whitsett JA. Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res 1992, 52(19):5342-5352.
30. Team TNLSTR Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England J Med 2011, 365(5):395-409. Team TNLSTR.
31. Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE. Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother 1995, 41(5):287-292.
32. Juffrie M, Meer GM, Hack CE, Haasnoot K, Sutaryo, Veerman AJ, Thijs LG. Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. The Am J Trop Med Hyg 2001, 65(1):70-75.
33. Ogawa M, Sato N, Endo S, Kojika M, Yaegashi Y, Kimura Y, Ikeda K, Iwaya T. Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery. Surgery Today 2005, 35(11):912-918. 10.1007/s00595-005-3059-7, 16249843.
34. Wootton PT, Drenos F, Cooper JA, Thompson SR, Stephens JW, Hurt-Camejo E, Wiklund O, Humphries SE, Talmud PJ. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Human Mol Genet 2006, 15(2):355-361.
35. Yamaguchi O, Sugimura K, Ishizuka K, Suzuki K, Hasegawa K, Ohtsuka K, Honma T, Asakura H. Correlation between serum phospholipase A(2) IIA levels and histological activity in patients with ulcerative colitis. Int J Colorectal Dis 2002, 17(5):311-316. 10.1007/s00384-002-0402-y, 12172924.
36. Serdar MA, Oguz O, Olgun A, Seckin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together. Ann Clin Lab Sci 2002, 32(1):22-30.
37. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. The New England J Med 1991, 324(17):1156-1161.
38. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. European urology 2005, 48(3):386-399. discussion 398-389, 10.1016/j.eururo.2005.04.015, 15982797.
39. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000, 55(6):791-795. 10.1016/S0090-4295(99)00602-0, 10840078.
40. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. The New England J Med 2004, 350(22):2239-2246.
41. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005, 65(3):549-553. 10.1016/j.urology.2004.10.064, 15780374.
42. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, Sesti R, Tripi S, Montalto G. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003, 23(2C):1747-1753.
43. el-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005, 12(4):248-253.
44. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004, 20(2):53-70.
45. Buchen L. Cancer: Missing the mark. Nature 2011, 471(7339):428-432. 10.1038/471428a, 21430749.